

Immunosuppressant. The action of Rapamuna is due to the suppression of T-cell activation by blocking Ca2 + -mediated and Ca2 + -independent intracellular signal transduction; binding with a specific cytosolic protein - immunophilin. Reduces the activity of T-and B-lymphocytes and suppresses the rejection of allogeneic transplant.
Prevention of transplant rejection (in adult patients with low and moderate immunological risk after kidney transplantation, in combination with GCS and cyclosporin).
1 tablet contains Sirolimus 1 mg
No customer reviews for the moment.
Rapamun is taken orally. It is recommended to use in combination with corticosteroids and cyclosporine for 2-3 months. Supportive therapy, if necessary, can be continued in combination with the corticosteroids without cyclosporine.
Initial therapy (within 2-3 months after transplantation): saturating dose - 6 mg once within 48 hours after transplantation, then maintenance dose of 2 mg / day. In the future, the dose should be chosen so that Cmin in the blood is in the range of 4-12 ng / ml (chromatographic method). Cmin of cyclosporine in the blood during the first 2-3 months after transplantation should be maintained at the level of 150-400 ng / ml (monoclonal concentration method).
From the lymphatic system: very often (10%) - lymphocele.
On the part of the body as a whole: often (1-10%) - impaired wound healing, edema, development or aggravation of fungal, viral and bacterial infections (including those caused by mycobacteria and Epstein-Barr virus).
On the part of the liver: possibly - hepatotoxicity, including fatal liver necrosis.
These side effects were observed with combination therapy with sirolimus and cyclosporine.
Pregnancy, lactation, childhood and adolescence, hypersensitivity to sirolimus.
Therapy should be carried out by a doctor who has relevant experience in transplantology.